

Supplementary table 1 Baseline characteristics of patients with all forms of PAH

Source	PAH agent	Female, <i>n</i> (%)	Mean age (years)	Mean weight (kg)	WHO functional class, <i>n</i> (%)				Mean baseline 6MWD (m)	Mean PAP (mmHg)
					I	II	III	IV		
Galiè <i>et al.</i> (2005) ¹⁵	Sildenafil	209 (76)	49	72.7	1 (1)	107 (39)	160 (58)	9 (3)	343.7	52.8
Singh <i>et al.</i> (2006) ¹⁶	Sildenafil	15 (75)	NR	NR	0	8 (40)	11 (55)	1 (5)	262.0	95.4
Simonneau <i>et al.</i> (2008) ¹⁷	Sildenafil	213 (80)	48	71.4	3 (1)	68 (26)	175 (66)	16 (6)	345.3	51.7
Galiè <i>et al.</i> (2009) ¹⁸	Tadalafil	317 (78)	54	75.4	4 (1)	130 (32)	264 (65)	7 (2)	343.6	53.2
Channick <i>et al.</i> (2001) ¹⁹	Bosentan	28 (85)	51	86.3	0	0	32 (100)	0	358.3	54.7
Rubin <i>et al.</i> (2002) ²⁰	Bosentan	168 (79)	48	71.9	0	0	195 (92)	18 (9)	334.5	54.4
Galiè <i>et al.</i> (2006) ²¹	Bosentan	33 (61)	39	63.7	0	0	54 (100)	0	342.8	76.0
Galiè <i>et al.</i> (2008) ²²	Bosentan	129 (70)	45	68.1	0	185 (100)	0	0	434.5	52.4
Galiè (2008) ²³	Ambrisentan	311 (79)	51	72.1	8 (2)	151 (38)	216 (55)	18 (5)	344.6	49.2
Rubin <i>et al.</i> (1990) ²⁴	Epoprostenol	16 (70)	36	NR	0	2 (9)	15 (65)	6 (26)	226.6	60.3
Barst <i>et al.</i> (1996) ²⁵	Epoprostenol	59 (73)	40	NR	0	0	60 (74)	21 (26)	294.3	60.0
Badesch <i>et al.</i> (2000) ²⁶	Epoprostenol	96 (87)	55	NR	0	5 (5)	87 (78)	19 (17)	255.9	50.0
Galiè <i>et al.</i> (2002) ²⁷	Beraprost	80 (62)	46	NR	0	64 (49)	66 (51)	0	372.5	59.5
McLaughlin <i>et al.</i> (2006) ²⁸	Inhaled iloprost	53 (79)	50	NR	0	1 (2)	63 (94)	3 (5)	335	52

Hoeper <i>et al.</i> (2006) ²⁹	Inhaled iloprost	31 (78)	52	NR	0	0	40 (100)	0	306.0	56.6
Simonneau (2002) ³⁰	Treprostinil	382 (81)	45	NR	0	53 (11)	382 (81)	34 (7)	326.5	61.0
McLaughlin <i>et al.</i> (2003) ³¹	Treprostinil	21 (81)	37	NR	0	25 (96)	1 (4)	0	376.8	60.7
McLaughlin <i>et al.</i> (2010) ³²	Treprostinil	191 (81)	54	NR	0	0	230 (98)	5 (2)	348.6	NR
Hiremath <i>et al.</i> (2010) ³³	Treprostinil	27 (61)	32	47	0	0	42 (95)	2 (5)	250.4	65

NR, not reported, PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; 6MWD, 6-minute walk distance; WHO, World Health Organisation.

Supplementary table 2 Baseline characteristics of patients with CTD-PAH

Study	PAH agent	Female, <i>n</i> (%)	Mean age (years)	Mean weight (kg)	WHO functional class, <i>n</i> (%)				Mean baseline 6MWD (m)	Mean PAP (mmHg)
					I	II	III	IV		
Badesch <i>et al.</i> (2007) ³⁴	Sildenafil	70 (83)	53	NR	0	32 (38)	51 (61)	1 (1)	342	47
Galiè <i>et al.</i> (2009) ¹⁸	Tadalafil	NR	NR	NR	NR	NR	NR	NR	NR	NR
Denton <i>et al.</i> (2006) ³⁵	Bosentan	55 (83)	55	NR	0	0	63 (96)	3 (5)	328.3	46.4
Launay <i>et al.</i> (2010) ³⁶	Bosentan	36 (74)	NR	NR	0	6 (12)	38 (78)	5 (10)	268	46
Badesch (2007) ³⁷	Ambrisentan	NR	NR	NR	NR	NR	NR	NR	335	NR
Badesch <i>et al.</i> (2012) ³⁸	Ambrisentan	36 (90)	55	NR	0	12 (30)	27 (68)	1 (3)	324	45
Badesch <i>et al.</i> (2000) ²⁶	Epoprostenol	96 (87)	55	NR	0	5 (5)	87 (78)	19 (17)	255.9	50.0
Kunieda <i>et al.</i> (2009) ³⁹	Beraprost	18 (95)	45	47.6	3 (16)	12 (63)	4 (21)	0	367.9	39.2
Oudiz <i>et al.</i> (2004) ⁴⁰	Treprostinil	81 (90)	51	NR	0	9 (10)	67 (74)	14 (16)	288.7	NR

CTD, connective tissue disease; NR, not reported; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; 6MWD, 6-minute walk distance; WHO, World Health Organisation.

Supplementary table 3 Risk of bias

Source	PAH agent	Random sequence generation	Allocation concealment	Blinding	Other source(s) of bias
All forms of PAH					
Galiè <i>et al.</i> (2005) ¹⁵	Sildenafil	Unclear	Low	Low	Low
Singh <i>et al.</i> (2006) ¹⁶	Sildenafil	Unclear	Low	Low	Low
Simonneau <i>et al.</i> (2008) ¹⁷	Sildenafil	Low	Low	Low	High
Galiè <i>et al.</i> (2009) ¹⁸	Tadalafil	Unclear	Unclear	Low	Low
Channick <i>et al.</i> (2001) ¹⁹	Bosentan	Low	Low	Low	Low
Rubin <i>et al.</i> (2002) ²⁰	Bosentan	Unclear	Unclear	Low	Low
Galiè <i>et al.</i> (2006) ²¹	Bosentan	Unclear	Low	Low	Low
Galiè <i>et al.</i> (2008) ²²	Bosentan	Low	Low	Low	Low
Galiè (2008) ²³	Ambrisentan	Unclear	Low	Low	Low
Rubin <i>et al.</i> (1990) ²⁴	Epoprostenol	Unclear	Low	High	Unclear
Barst <i>et al.</i> (1996) ²⁵	Epoprostenol	Low	Unclear	High	High
Badesch <i>et al.</i> (2000) ²⁶	Epoprostenol	Low	Unclear	High	Low
Galiè <i>et al.</i> (2002) ²⁷	Beraprost	Unclear	Unclear	Low	Low
McLaughlin <i>et al.</i> (2006) ²⁸	Inhaled iloprost	Low	Low	Low	Low
Hoeper <i>et al.</i> (2006) ²⁹	Inhaled iloprost	Low	Low	High	High
Simonneau (2002) ³⁰	Treprostiniil	Low	Unclear	Low	Low
McLaughlin <i>et al.</i> (2003) ³¹	Treprostiniil	Unclear	Unclear	Low	Low
McLaughlin <i>et al.</i> (2010) ³²	Treprostiniil	Unclear	Unclear	Low	Low
Hiremath <i>et al.</i> (2010) ³³	Treprostiniil	Unclear	Unclear	Low	Low
CTD-PAH					
Badesch <i>et al.</i> (2007) ³⁴	Sildenafil	Unclear	Low	Low	Low
Galiè <i>et al.</i> (2009) ¹⁸	Tadalafil	Unclear	Unclear	Low	Low
Denton <i>et al.</i> (2006) ³⁵	Bosentan	Unclear	Unclear	Low	High
Launay <i>et al.</i> (2010) ³⁶	Bosentan	High	High	High	High

Source	PAH agent	Random sequence generation	Allocation concealment	Blinding	Other source(s) of bias
Badesch (2007) ³⁷	Ambrisentan	Unclear	Low	Low	Unclear
Badesch <i>et al.</i> (2012) ³⁸	Ambrisentan	High	High	High	High
Badesch <i>et al.</i> (2000) ²⁶	Epoprostenol	Low	Unclear	No	Low
Kunieda <i>et al.</i> (2009) ³⁹	Beraprost	High	High	High	High
Oudiz <i>et al.</i> (2004) ⁴⁰	Treprostinil	Unclear	Unclear	Low	Low

CTD, connective tissue disease; PAH, pulmonary arterial hypertension.